Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

Summary

the investigators will conduct a phase II trial to evaluate the efficacy and toxicity of Sunitinib in patients with recurrent SCLC.

Timeline

Start

2008-03

Primary completion

2012-02

Completion

2012-09

Publications

• Han JY, Kim HY, Lim KY, Han JH, Lee YJ, Kwak MH, Kim HJ, Yun T, Kim HT, Lee JS. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer. 2013 Feb;79(2):137-42. doi: 10.1016/j.lungcan.2012.09.019. Epub 2012 Nov 20.

Drugs

Indications